aminoglycoside


Also found in: Medical, Wikipedia.
Related to aminoglycoside: metronidazole, vancomycin

a·mi·no·gly·co·side

 (ə-mē′nō-glī′kə-sīd′, ăm′ə-)
n.
Any of a group of broad-spectrum antibiotics, such as streptomycin, derived from species of Streptomyces or Micromonospora bacteria and used to treat infections caused by gram-negative bacteria.
Mentioned in ?
References in periodicals archive ?
Seattle, Washington-based biotech company Oricula Therapeutics, LLC has received permission from the FDA to begin volunteer human testing for safety, tolerability, and pharmacokinetics of ORC-13661 for the prevention of hearing loss in patients undergoing aminoglycoside treatment, the company said.
Under the company's animal studies, ORC-13661 provided highly significant protection of hearing in rats exposed to high doses of aminoglycoside antibiotics, a common cause of human hearing loss.
5] The emergence of multidrug resistant strains with high level aminoglycoside resistance (HLAR), [beta]-lactamase production and glycopeptide resistance including vancomycin resistant enterococci (VRE) results in therapeutic failure, posing a serious threat to the life of patients.
The CDC said CREs resistant to all antimicrobials "are very uncommon," with 80 percent susceptible to at least one aminoglycoside and nearly 90 percent susceptible to tigecycline.
The importance of this gene is elimination of synergistic effects between penicillin and glycopeptide or aminoglycoside antibiotics by encoding a bi functional enzyme (6,7).
Thus, there is an urgent need to develop safer aminoglycoside antibiotics.
The isolates were further screened for high-level aminoglycoside resistance by their ability to grow on Muller Hinton agar containing amikacin and gentamicin 256 mg/L each as a marker for 16S RMTase (3).
First isolated in the 1950s, several aminoglycoside antibiotics like neomycin were developed over the ensuing decades.
The fallacy of relying on Cr-based markers of GFR for adjustment of aminoglycoside dosing in the acute setting is correctly highlighted but this is not related to age.
Our study population was made up of 164 newborns who were divided into three groups: group A consisted of 105 infants who were given aminoglycoside therapy (either gentamicin or amikacin, or a combination of the two) as treatment for suspected or proven bacterial infection and septic states; group B included 30 newborns who were not given an antibiotic or who were given an antibiotic other than an aminoglycoside; group C, a control group, was made up of 29 healthy neonates who were hospitalized in the well-baby nursery.